Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaines

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 2, 2014, Pages 346-358

  Thurner, Patrick ^a   Stary Weinzinger, Anna ^b   Gafar, Hend ^a   Gawali, Vaibhavkumar S ^a   Kudlacek, Oliver ^a   Zezula, Juergen ^a   Hilber, Karlheinz ^a   Boehm, Stefan ^a   Sandtner, Walter ^a   Koenig, Xaver ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IBOGAINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL MEMBRANE DEPOLARIZATION; CELL MEMBRANE POTENTIAL; CHANNEL GATING; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; GENE; GENE MUTATION; HERG GENE; HIDDEN MARKOV MODEL; KIDNEY CELL; MOLECULAR DOCKING; NONHUMAN; PH; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTON TRANSPORT; STEADY STATE;

EID: 84893044001     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.209643     Document Type: Article

References (57)

1. Alper KR (2001) Ibogaine: a review. Alkaloids Chem Biol 56:1-38.
2. Alper KR, Lotsof HS, and Kaplan CD (2008) The ibogaine medical subculture. J Ethnopharmacol 115:9-24.
3. Alper KR, Stajic M, and Gill JR (2012) Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci 57:398-412.
4. Bérubé J, Chahine M, and Daleau P (1999) Modulation of HERG potassium channel properties by external pH. Pflugers Arch 438:419-422.
5. Bett GCL, Zhou Q, and Rasmusson RL (2011) Models of HERG gating. Biophys J 101: 631-642.
6. Chen J, Zou A, Splawski I, Keating MT, and Sanguinetti MC (1999) Long QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation. J Biol Chem 274:10113-10118.
7. DeCoursey TE (1995) Mechanism of K1 channel block by verapamil and related compounds in rat alveolar epithelial cells. J Gen Physiol 106:745-779.
8. Dong D-L, Li Z, Wang H-Z, Du Z-M, Song W-H, and Yang B-F (2004) Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels. Basic Clin Pharmacol Toxicol 94:209-212.
9. Dumaine R, Roy ML, and Brown AM (1998) Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther 286:727-735.
10. Ficker E, Jarolimek W, Kiehn J, Baumann A, and Brown AM (1998) Molecular determinants of dofetilide block of HERG K1 channels. Circ Res 82:386-395.
11. Fink M and Noble D (2009) Markov models for ion channels: versatility versus identifiability and speed. Philos Trans A Math Phys Eng Sci 367:2161-2179.
12. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, et al.(2009) Gaussian 09, Revision A.1 Gaussian, Inc., Wallingford, CT.
13. Ganapathi SB, Kester M, and Elmslie KS (2009) State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Am J Physiol Cell Physiol 296:C701-C710.
14. Guo J, Gang H, and Zhang S (2006) Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels. J Pharmacol Exp Ther 317: 865-874.
15. Hoelen DWM, Spiering W, and Valk GD (2009) Long-QT syndrome induced by the antiaddiction drug ibogaine. N Engl J Med 360:308-309.
16. Horn R (1987) Statistical methods for model discrimination. Applications to gating kinetics and permeation of the acetylcholine receptor channel. Biophys J 51: 255-263.
17. Jalal S, Daher E, and Hilu R (2013) A case of death due to ibogaine use for heroin addiction: case report. Am J Addict 22:302.
18. Kamiya K, Niwa R, Morishima M, Honjo H, and Sanguinetti MC (2008) Molecular determinants of hERG channel block by terfenadine and cisapride. J Pharmacol Sci 108:301-307.
19. Kiehn J, Thomas D, Karle CA, Schöls W, and Kübler W (1999) Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol 359:212-219.
20. Kirsch GE and Narahashi T (1983) Site of action and active form of aminopyridines in squid axon membranes. J Pharmacol Exp Ther 226:174-179.
21. Koenig X, Kovar M, Boehm S, Sandtner W, and Hilber K (2012) Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk. Addict Biol 10.1111/ j.1369-1600.2012.00447.x.
22. Koenig X, Kovar M, Rubi L, Mike AK, Lukacs P, Gawali VS, Todt H, Hilber K, and Sandtner W (2013) Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug's cardiac ion channel profile. Toxicol Appl Pharmacol 273:259-268
23. Leung Y-M (2012) Involvement of C-type inactivation gating in the actions of voltagegated K1 channel inhibitors. Pharmacol Ther 133:151-158.
24. Maas U and Strubelt S (2006) Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction. Med Hypotheses 67:960-964.
25. Maciulaitis R, Kontrimaviciute V, Bressolle FMM, and Briedis V (2008) Ibogaine, an anti-addictive drug: pharmacology and time to go further in development: a narrative review. Hum Exp Toxicol 27:181-194.
26. Mash DC, Kovera CA, Buck BE, Norenberg MD, Shapshak P, Hearn WL, and Sanchez-Ramos J (1998) Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann N Y Acad Sci 844:274-292.
27. Mazoyer C, Carlier J, Boucher A, Péoc'h M, Lemeur C, and Gaillard Y (2013) Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material. J Forensic Sci 58:1666-1672.
28. Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, and Hancox JC (2006) hERG K1 channel blockade by the antipsychotic drug thioridazine: an obligatory role for the S6 helix residue F656. Biochem Biophys Res Commun 351: 273-280.
29. Mitcheson JS, Chen J, Lin M, Culberson C, and Sanguinetti MC (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97: 12329-12333.
30. Nakajima T, Furukawa T, Tanaka T, Katayama Y, Nagai R, Nakamura Y, and Hiraoka M (1998) Novel mechanism of HERG current suppression in LQT2: shift in voltage dependence of HERG inactivation. Circ Res 83:415-422.
31. Paling FP, Andrews LM, Valk GD, and Blom HJ (2012) Life-threatening complications of ibogaine: three case reports. Neth J Med 70:422-424.
32. Papadodima SA, Dona A, Evaggelakos CI, Goutas N, and Athanaselis SA (2013) Ibogaine related sudden death: a case report. J Forensic Leg Med 20: 809-811.
33. Perrin MJ, Kuchel PW, Campbell TJ, and Vandenberg JI (2008) Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels. Mol Pharmacol 74: 1443-1452.
34. Perry M, Sanguinetti M, and Mitcheson J (2010) Revealing the structural basis of action of hERG potassium channel activators and blockers. J Physiol 588: 3157-3167.
35. Pleskovic A, Gorjup V, Brvar M, and Kozelj G (2012) Ibogaine-associated ventricular tachyarrhythmias. Clin Toxicol (Phila) 50:157.
36. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PKS, Strang I, Sullivan AT, and Wallis R, et al. (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32-45.
37. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, and Thomas SH (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355: 1048-1052.
38. Ridley JM, Milnes JT, Duncan RS, McPate MJ, James AF, Witchel HJ, and Hancox JC (2006) Inhibition of the HERG K1 channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656. FEBS Lett 580: 1999-2005.
39. Sánchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, and Sanguinetti MC (2002) Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K1 channel block. J Biol Chem 277:23587-23595.
40. Sánchez-Chapula JA, Navarro-Polanco RA, and Sanguinetti MC (2004) Block of wildtype and inactivation-deficient human ether-a-go-go-related gene K1 channels by halofantrine. Naunyn Schmiedebergs Arch Pharmacol 370:484-491.
41. Sanguinetti MC and Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440:463-469.
42. Smith PL, Baukrowitz T, and Yellen G (1996) The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379:833-836.
43. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, and Vincent GM,, et al. (2000) Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 102:1178-1185.
44. Stary A, Wacker SJ, Boukharta L, Zachariae U, Karimi-Nejad Y, Aqvist J, Vriend G, and de Groot BL (2010) Toward a consensus model of the HERG potassium channel. ChemMedChem 5:455-467.
45. Thomas D, Wu K, Kathöfer S, Katus HA, Schoels W, Kiehn J, and Karle CA (2003) The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol 139:567-574.
46. Tie H, Walker BD, Singleton CB, Valenzuela SM, Bursill JA, Wyse KR, Breit SN, and Campbell TJ (2000) Inhibition of HERG potassium channels by the antimalarial agent halofantrine. Br J Pharmacol 130:1967-1975.
47. Trudeau MC, Warmke JW, Ganetzky B, and Robertson GA (1995) HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269: 92-95.
48. Tseng GN (2001) I(Kr): the hERG channel. J Mol Cell Cardiol 33:835-849.
49. Tsujimae K, Suzuki S, Yamada M, and Kurachi Y (2004) Comparison of kinetic properties of quinidine and dofetilide block of HERG channels. Eur J Pharmacol 493:29-40.
50. Vandenberg JI, Walker BD, and Campbell TJ (2001) HERG K1 channels: friend and foe. Trends Pharmacol Sci 22:240-246.
51. Vastag B (2005) Addiction research: ibogaine therapy: a 'vast, uncontrolled experiment'. Science 308:345-346.
52. Vlaanderen L and Martial L (2013) Cardiac arrest after ibogaine ingestion. J Clin Toxicol 01:10-13.
53. Walker BD, Singleton CB, Bursill JA, Wyse KR, Valenzuela SM, Qiu MR, Breit SN, and Campbell TJ (1999) Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br J Pharmacol 128:444-450.
54. Walker BD, Singleton CB, Tie H, Bursill JA, Wyse KR, Valenzuela SM, Breit SN, and Campbell TJ (2000) Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel. Cardiovasc Res 48:44-58.
55. Wang S, Liu S, Morales MJ, Strauss HC, and Rasmusson RL (1997a) A quantitative analysis of the activation and inactivation kinetics of HERG expressed in Xenopus oocytes. J Physiol 502:45-60.
56. Wang S, Morales MJ, Liu S, Strauss HC, and Rasmusson RL (1997b) Modulation of HERG affinity for E-4031 by [K1]o and C-type inactivation. FEBS Lett 417: 43-47.
57. Zhang S, Zhou Z, Gong Q, Makielski JC, and January CT (1999) Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84:989-998.